Fig. 3From: Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocolImpact of the cetuximab-taxane recurrency scheme on DFS and OS. a displays the disease-free survival (DFS) and b the overall survival (OS) of the study group (magenta) and the matched pair control group (blue). DFS enhanced about 4.8 months (p = 0.13) and OS about 8.7 months (p = 0.023)Back to article page